CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Entropy Neurodynamics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Entropy Neurodynamics Ltd
Suite 201, 697 Burke Road, Camberwell
Phone: +61 384190827p:+61 384190827 MELBOURNE, VIC  3124  Australia Ticker: ENPENP
Business Summary
Entropy Neurodynamics Limited, formerly Tryptamine Therapeutics Limited, is an Australia-based clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company’s lead program, TRP-8803, is a proprietary formulation of IV infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder and for the treatment of fibromyalgia. Each of the studies is utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20256/30/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board HerwigJanssen 5/12/2025 5/12/2025
Chief Executive Officer, Director Jason A.Carroll 4/11/2024 10/1/2023
Chief Financial Officer, Company Secretary HamishGeorge 3/31/2025 9/1/2024
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Tryp Therapeutics Inc 301 - 1665 Ellis Street KELOWNA BC Canada

Business Names
Business Name
ENP
EX1
EX1DA
Tryp Therapeutics Inc
TYP

General Information
Outstanding Shares: 1,438,921,585 (As of 6/30/2025)
Shareholders: 2,169
Stock Exchange: ASX


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, November 23, 2025